Skip to content

How it works
wikifolios
- Highlights
- Search
News & Insights
- Blog
- Stock Insights
Help
- FAQ
- Contact

See all wikifolios

wikifolios

Highlights
Search

News & Insights

Blog
Stock Insights

Help

FAQ
Contact

See all wikifolios

mathias Hennebellle

Frenchie
Last login 2024-01-07
Member since 2014-08-28

Top wikifolio
TIFFANY

Frenchie
+149.9 %

since Beginning

+2.1 %

1 Year
TOP WIKIFOLIO TRADE
- Sell 2015-02-13 at 07:58 pm
  
  ELI LILLY
  
  US5324571083
  
  Price (EUR) 61.730
Last Activity

Chelsea

AbbVie Inc. (ABBV) has agreed to provide its breakthrough, $1,000-a-day hepatitis C treatment to state-based HIV drug programs at a substantial discount, according to a group that negotiates drug pricing for the programs. The ADAP Crisis Task Force negotiates for the 50-plus such programs and served about 150,000 patients in June 2013, said Britten Pund, associate director of health-care access for the National Alliance of State & Territorial AIDS Directors. The group doesn’t have any deal with Gilead Sciences Inc. (GILD), which sells the competing medicines Sovaldi and Harvoni. AbbVie’s drug, Viekira Pak, requires patients to take more pills a day than Gilead’s treatment. “The task force had previously tried to negotiate with Gilead on the price of Sovaldi, and Gilead had declined to negotiate,” Pund said in a telephone interview. “We did not have a specific conversations about Harvoni, but we hope to reignite those conversations.” Cara Miller, a Gilead spokeswoman, declined to comment. About 30 percent of people with HIV are also estimated to be infected with hepatitis C, according to the group. AbbVie and Gilead have been negotiating with insurers and pharmacy benefit managers to gain traction on lists of drugs covered by health insurers and state programs. Aetna Inc., for example, announced a deal Friday with Gilead giving preference to its drugs.
Show comment

wikifolios

About

[Beschreiben Sie, Ihre Erfahrung mit Wertpapieren….] [Beschreiben Sie, wie Sie zum Handel mit Wertpapieren gekommen sind….] [Beschreiben Sie, welche Trading-Erfolge Sie in der Vergangenheit hatten......] [Beschreiben Sie, Ihre Gedanken zur aktuellen Marktlage….] [Beschreiben Sie, wie viel Zeit sie für Ihre Handelsidee aufwenden….] show more

Experience in securities trading

Risk class 1: 0 to 1 year

Risk class 2: 0 to 1 year

Risk class 3: 0 to 1 year

Risk class 4: 0 to 1 year

Risk class 5: 0 to 1 year

Questions? Visit our FAQ or contact us:

+49 (0) 211 247 907 70 service@wikifolio.com

Discover

Current wikifolios
Investment trends
wikifolio traders

Help

FAQ
Contact
How it works

wikifolio

About
Jobs
Partners

© 2024 wikifolio Financial Technologies AG GTC Imprint Data protection Cookie declaration